<DOC>
	<DOC>NCT01767519</DOC>
	<brief_summary>A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.</brief_summary>
	<brief_title>A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Symptoms of Overactive Bladder (OAB) (frequency/urgency) with urinary incontinence for at least 6 months Inadequate response or limiting side effects with anticholinergics for the treatment of OAB Overactive Bladder caused by neurological condition Patient has predominance of stress incontinence Use of anticholinergics or other medications to treat OAB symptoms in the 7 days prior to screening Previous use of solifenacin History or evidence of pelvic or urological abnormality Previous use of any botulinum toxin of any serotype for any urological condition Previous use of any botulinum toxin of any serotype for any nonurological condition within 12 weeks of randomization Diagnosis of Myasthenia gravis, EatonLambert Syndrome, Amyotrophic Lateral Sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>